Health Canada Authorized Moderna's Spikevax BA.4/5 Bivalent Covid Vaccine For Use As A Booster Dose In Children And Adolescents 6-17 Years Of Age
Portfolio Pulse from Happy Mohamed
Health Canada has authorized Moderna's Spikevax BA.4/5 bivalent COVID-19 vaccine for use as a booster dose in children and adolescents aged 6-17 years.

May 18, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's Spikevax BA.4/5 bivalent COVID-19 vaccine has been authorized by Health Canada for use as a booster dose in children and adolescents aged 6-17 years.
The authorization of Moderna's Spikevax BA.4/5 bivalent COVID-19 vaccine for use as a booster dose in children and adolescents aged 6-17 years by Health Canada is a positive development for the company. This approval expands the market for Moderna's vaccine, potentially increasing demand and revenues. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100